Syros Pharmaceuticals Inc (NAS:SYRS)
$ 1.5675 -0.035 (-2.18%) Market Cap: 42.02 Mil Enterprise Value: 24.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q3 2021 Syros Pharmaceuticals Inc Earnings Call Transcript

Nov 05, 2021 / 12:30PM GMT
Release Date Price: $45.6 (+3.17%)
Operator

Good day, and thank you for standing by. Welcome to the Q3 2021 Syros Pharmaceuticals, Inc. Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Courtney Solberg with Syros. Please go ahead.

Courtney Solberg

Thank you. This morning, we issued a press release with our third quarter 2021 financial results along with anticipated future milestones and recent accomplishments. This release is available on the Investors and Media section of Syros' website at www.syros.com.

We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; Kristin Stephens, our Chief Development Officer; and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Dr. Eric Olson, our Chief Scientific Officer; and Conley Chee, our Chief Commercial Officer, are also on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot